Type2 Diabetes Clinical Trial
Official title:
Multi Center Clinical Study of Chinese Medicine Intervention on Early Diabetic Microvascular Complications: Multi Centers Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy
This study include 384 Participants with diabetic non-proliferative retinopathy
Design Method: Randomized, double blind, placebo controlled and multicenter clinical study.
Participants treatment for 48 weeks, and main aimed to evaluate the therapeutic effect of
tang wang prescription improve degree of retinal microvascular disease of patients with
diabetic non-proliferative retinopathy.
1. This study is a randomized, double-blinded, placebo-controlled and multicenter clinical
trial on type 2 diabetic non-proliferative retinopathy to evaluate the therapeutic
effect of tang wang prescription.
2. Through the calculation of sample size, 384 participants with type 2 diabetic
non-proliferative retinopathy will be recruited for the study, all participants were
randomly divided into 2 groups, and both of groups would be performed on a basic
treatment (including diabetes education, diabetes diet, rational control of blood
glucose (oral hypoglycemic agents or insulin injections to keep all participants keep
blood glucose stable in the study. If fasting blood glucose fluctuates more than 20%,
need to find and remove the factors as soon as possible, and adjust the dose and
monitor change of blood glucose, make it smooth in 4 weeks. Adjusted dose of the drug
needs to be detailed records in the combined medication table), and oral calcium
dobesilate treatment), study group take tang wang prescription, take one bag each time
and twice on day, control group take the same dose of placebo.
3. The study will last for 48 weeks. Once every four weeks follow-up, color fundus
photography, fundus fluorescein angiography, and coherent optical tomography were
performed every six months; ETDRS international visual acuity test was performed every
months.
4. Curative effect evaluation criteria:
- Main evaluation criteria: the changes of degree of retinal microvascular lesions
before and after treatment, according to the change of degree of retinal
microvascular lesions (no, mild non proliferative phase, moderate non
proliferative phase, severe non proliferative phase, proliferative phase), divided
into aggravated, unchanged, reduce three conditions. Aggravated was defined as the
degree of retinal microvascular lesions severity more than grade 1 after
treatment; unchanged was defined as the degree of retinal microvascular lesions
before and after treatment did not change; reduce was defined as the degree of
retinal microvascular lesions reduced more than 1 grade after treatment.
- Second evaluation criteria:
- Change of the number of micro hemangioma of diabetic retinopathy before and
after treatment;
- Change of the number of microvascular bleeding of diabetic retinopathy before
and after treatment;
- Change of the number of microvascular leakage of diabetic retinopathy before
and after treatment;
- Degree of change of macular edema of diabetic retinopathy before and after
treatment;
- Change of Vision before and after treatment.
5. Diagnostic and monitoring indicators:blood pressure, fasting blood glucose test (every
one month); glycated hemoglobin, blood lipids (every three months); Routine eye
examination and fundus examination, including intraocular pressure, anterior segment,
lens, vitreous body, and lens, vitreous need describe the conditions of opacity (every
six months).
6. The provisions of the combined therapy
- All Chinese herbal medicines with the same efficacy as the study drug (including
Chinese herbal medicines with similar therapeutic and similar efficacy in
Instructions) were banned during the study period.
- All combined therapy and Combined medication(treatment measure or treatment
medicine of other diseases) should be recorded in the combined medication table.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03239366 -
A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population
|
Phase 2 | |
Completed |
NCT04597229 -
Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
|
N/A | |
Completed |
NCT03623139 -
Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT04599920 -
Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)
|
N/A | |
Active, not recruiting |
NCT03422471 -
Hypoglycemia and Autonomic Nervous System Function- B2
|
N/A | |
Completed |
NCT04382521 -
A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions
|
N/A | |
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Recruiting |
NCT03458715 -
The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
|
Phase 4 | |
Terminated |
NCT03278236 -
Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?
|
N/A | |
Completed |
NCT02974504 -
Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)
|
Phase 4 | |
Completed |
NCT05053828 -
Type 2 Diabetes With Antiplatelet Drugs
|
||
Not yet recruiting |
NCT03659383 -
The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine
|
Phase 4 | |
Completed |
NCT03542240 -
Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome
|
N/A | |
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT03979768 -
Risk Assessment of Type 2 Diabetes in Pharmacies
|
N/A | |
Completed |
NCT03614039 -
Effect of Probiotic and Smectite Gel on NAFLD
|
N/A | |
Active, not recruiting |
NCT04994288 -
A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients
|
Phase 2/Phase 3 | |
Completed |
NCT03290768 -
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
|
N/A | |
Enrolling by invitation |
NCT04088851 -
"The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"
|
N/A | |
Completed |
NCT03643783 -
Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients
|